Jaguar Gene Therapy

Jaguar Gene Therapy is a private, pre-revenue biotech focused on developing gene therapies for severe genetic diseases using the well-characterized AAV platform. The company emphasizes product purity, patient safety, and a scalable manufacturing process from the outset of its programs. Its leadership team includes veterans with prior experience in successfully developing, manufacturing, and launching an FDA-approved systemic gene therapy, providing a significant operational advantage. Jaguar is rapidly advancing its pipeline while evaluating next-generation technologies for future programs.

Leverages a proven and well-characterized AAV (adeno-associated virus) gene therapy platform with a focus on best-in-class manufacturing for high purity. Also evaluating next-generation technologies including novel capsids and delivery methods.

Operates in the highly competitive gene therapy sector, competing with large pharmaceutical companies, established biotechs, and other well-funded startups. Its key differentiator is a leadership team with prior success in taking a systemic gene therapy from development through FDA approval and launch.